Corporate Strategy

NPIL's medium-term business model envisages achieving leadership in the domestic pharmaceuticals market, and building a strong de-risked international business around our core strengths in manufacturing, marketing and R&D.

NPIL has some of the strongest brands in India and a demonstrated ability to build brands and leadership through markets characterized by intense competition. The company's strategy of leveraging its competencies, built assiduously over the years through a growing domestic market, and addressing manufacturing opportunities in the developed global pharmaceutical markets sharply defines our strategic intent.

The Indian domestic market is significant since it represents the base on which NPIL is building a global business model. India represents a sixth of humanity. Although buying power and pharmaceuticals penetration is currently lower than some of the more developed markets, it is expected to grow to US $ 25 billion by the year 2010.

Nicholas Piramal India Limited has an unmatched record of managing Joint Ventures/Alliances/Partnerships and a proven commitment to IPR. Capabilities include sales & marketing, a US FDA site-approved plant for on-and-off patent APIs and Intermediates, Basic Research, process innovation, Custom Chemical Synthesis, Formulations R&D, NDDS, and a world-class Clinical Research Organisation.